Clinical consensus now endorses the broader adoption of dual GIP/GLP-1 agonists like tirzepatide and GLP-1 receptor agonists such as semaglutide, highlighting their robust benefits in weight loss, glycemic control, and cardiovascular risk reduction. With no significant safety conflicts, experts urge standardized monitoring and continued long-term safety research, while emphasizing the need for patient education on informed usage. This development signals a shift towards more effective integrated management strategies for type 2 diabetes and obesity.
Title not available for this citation.
“Tirzepatide is widely prescribed and generally considered safe.”
Title not available for this citation.
“A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.”
Title not available for this citation.
“Following drug discontinuation, liver enzymes normalized after 24 days.”
Title not available for this citation.
“Semaglutide and tirzepatide have shown clinically meaningful weight loss in clinical trials.”
Title not available for this citation.
“The final sample included 8 participants (100 % female, mean age 42).”
Title not available for this citation.
“The findings suggest the medications provide a sense of hope for effective treatment.”
Title not available for this citation.
“At 72 weeks of therapy, patients had lost an average of -62.79 lbs (-26.54 %).”
Title not available for this citation.
“PIONEER REAL Saudi Arabia investigated real-world clinical outcomes associated with the use of once-daily oral semaglutide in adults with type 2 diabetes (T2D). In total, 192 participants initiated oral semaglutide.”
Title not available for this citation.
“This real-world population of adults with T2D in Saudi Arabia experienced clinically significant reductions in HbA1c and BW, consistent with previously published PIONEER REAL studies.”
Title not available for this citation.
“Treatment satisfaction increased significantly (mean change in DTSQs +8.7 and DTSQc 14.9; both p < 0.0001).”
Title not available for this citation.
“Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated robust evidence across randomized controlled trials and real-world studies in improving glycemic control (mean glycated hemoglobin [HbA1c] reduction of 1.0-1.5%)...”
Title not available for this citation.
“Semaglutide... inducing sustained weight loss (average 10-15%)...”